Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Karo Pharma AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Karo Pharma AB, Medical Devices Deals, 2012 to YTD 2018 10
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Karo Pharma AB, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Karo Pharma Acquires Product Portfolio of Ten Products from LEO Pharma for USD317.6 Million 12
Private Equity 14
EQT VIII to Acquire Karo Pharma for USD652.6 Million 14
Partnerships 15
Karo Bio Enters Into Research Agreement With 4D Science 15
Licensing Agreements 16
Karo Pharma Enters into Licensing Agreement with Marinomed Biotech 16
Weifa Enters into Licensing Agreement with AFT Pharma 17
Karo Bio Enters into Licensing Agreement with Pelago Bioscience for CETSA 18
Equity Offering 19
Karo Pharma Raises USD151.5 Million in Rights Offering of Shares 19
Karo Bio to Raise USD29.7 Million in Rights Offering of Preferred Shares 20
Weifa Raises USD13.6 Million in Private Placement of Shares 21
Karo Bio Raises USD29 Million in Rights Offering of Shares 22
Aqualis to Raise USD116.7 Million in Private Placement of Shares 23
Aqualis to Raise USD16.7 Million in Rights Offering of Shares 24
Karo Bio Raises USD12 Million in Rights Offering of Shares 25
Karo Bio Raises USD1 Million in Private Placement of Shares 26
Aqualis Completes Private Placement Of Shares For US$4 Million 27
Aqualis Completes Private Placement Of Shares For US$4.7 Million 28
Aqualis Completes Rights Offering Of Shares For US$9 Million 29
Karo Bio Completes Rights Offering of Shares for USD4.9 Million 30
Debt Offering 31
Aqualis to Raise USD66.7 Million in Public Offering of Bonds 31
Asset Transactions 32
Oasmia Pharma Acquires Cancer Project KB9520 from Karo Pharma 32
Acquisition 33
Karo Pharma Acquires Weifa 33
Karo Pharma Acquires 100% Stake in Medireduce 35
Karo Pharma Acquires BioPhausia from Medivir for USD95 Million 36
Karo Bio Acquires Tanomed for USD2.3 Million 37
Aqualis Completes Acquisition of Weifa for USD183.6 Million 38
Karo Pharma AB – Key Competitors 39
Karo Pharma AB – Key Employees 40
Karo Pharma AB – Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 42
Financial Announcements 42
Jul 19, 2018: Karo pharma triples sales and profit in the second quarter 42
Apr 26, 2018: Karo Pharma Doubles Sales and Earnings in the First Quarter 44
Feb 22, 2018: Karo Pharma: Year-end Report 2017 45
Nov 02, 2017: Karo Pharma: Interim Report January– September 2017 46
Aug 24, 2017: Karo Pharma: Interim Report January–June 2017 48
May 10, 2017: Karo Pharma: interim report January – March-2017 49
Feb 28, 2017: Karo Pharma: Full Year Report 2016 50
Corporate Communications 51
Mar 23, 2018: Karo Pharma Supports Operation Smile 51
Product News 52
05/21/2018: UTILITY Therapeutics Receives Qualified Infectious Disease Product Designation from the U.S. FDA for Mecillinam 52
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53
Karo Pharma AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Karo Pharma AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Karo Pharma AB, Deals By Therapy Area, 2012 to YTD 2018 9
Karo Pharma AB, Medical Devices Deals, 2012 to YTD 2018 10
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Karo Pharma Acquires Product Portfolio of Ten Products from LEO Pharma for USD317.6 Million 12
EQT VIII to Acquire Karo Pharma for USD652.6 Million 14
Karo Bio Enters Into Research Agreement With 4D Science 15
Karo Pharma Enters into Licensing Agreement with Marinomed Biotech 16
Weifa Enters into Licensing Agreement with AFT Pharma 17
Karo Bio Enters into Licensing Agreement with Pelago Bioscience for CETSA 18
Karo Pharma Raises USD151.5 Million in Rights Offering of Shares 19
Karo Bio to Raise USD29.7 Million in Rights Offering of Preferred Shares 20
Weifa Raises USD13.6 Million in Private Placement of Shares 21
Karo Bio Raises USD29 Million in Rights Offering of Shares 22
Aqualis to Raise USD116.7 Million in Private Placement of Shares 23
Aqualis to Raise USD16.7 Million in Rights Offering of Shares 24
Karo Bio Raises USD12 Million in Rights Offering of Shares 25
Karo Bio Raises USD1 Million in Private Placement of Shares 26
Aqualis Completes Private Placement Of Shares For US$4 Million 27
Aqualis Completes Private Placement Of Shares For US$4.7 Million 28
Aqualis Completes Rights Offering Of Shares For US$9 Million 29
Karo Bio Completes Rights Offering of Shares for USD4.9 Million 30
Aqualis to Raise USD66.7 Million in Public Offering of Bonds 31
Oasmia Pharma Acquires Cancer Project KB9520 from Karo Pharma 32
Karo Pharma Acquires Weifa 33
Karo Pharma Acquires 100% Stake in Medireduce 35
Karo Pharma Acquires BioPhausia from Medivir for USD95 Million 36
Karo Bio Acquires Tanomed for USD2.3 Million 37
Aqualis Completes Acquisition of Weifa for USD183.6 Million 38
Karo Pharma AB, Key Competitors 39
Karo Pharma AB, Key Employees 40
Karo Pharma AB, Subsidiaries 41
List of Figures
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Karo Pharma AB, Medical Devices Deals, 2012 to YTD 2018 10